Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

400
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
400
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

593
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
593
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

609
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
609
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

228
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
228
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

708
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
708
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

854
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
854

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enteric populations of <i>Escherichia coli</i> are likely to be resistant to phages due to O antigen expression.

mSphere·2026
Same author

Bacteriophage Heteroresistance as a Cause of Treatment Failure in Urinary Tract Infections.

bioRxiv : the preprint server for biology·2026
Same author

Global trends in norovirus genotype distribution among medically attended children with acute gastroenteritis, 2020-2025.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2026
Same author

High-resolution metabolomic analysis of stool reveals expanded biomarkers of <i>C. difficile</i> colitis and insights into pathophysiology.

Microbiology spectrum·2026
Same author

Fecal Microbiota Transplant for Multidrug Resistance-No Benefit Without Disruption?

JAMA internal medicine·2026
Same author

When probiotics guidelines differ: a practical guide for clinicians and researchers.

Gut microbes·2026

相关实验视频

Updated: Jan 8, 2026

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
06:55

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.

Published on: November 7, 2018

9.4K

最先进的技术审查:传染性腹.

Andi L Shane1, Mark D Gonzalez2, Amanda M Roy3

  • 1Division of Pediatric Infectious Disease, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

本综述概述了针对传染性腹管理的多学科方法,更新了指导方针,并讨论了诊断,表现和新兴的治疗方法,如生物疗法,以减少疾病负担.

关键词:
诊断 诊断 诊断 诊断 诊断腹 腹 腹 腹 腹 腹传染性 传染性 传染性管理的管理管理的管理.预防 预防 预防

更多相关视频

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
04:56

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections

Published on: February 9, 2024

1.4K
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases &#8212; Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.5K

相关实验视频

Last Updated: Jan 8, 2026

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
06:55

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.

Published on: November 7, 2018

9.4K
Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
04:56

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections

Published on: February 9, 2024

1.4K
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases &#8212; Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.5K

科学领域:

  • 传染性疾病 传染性疾病
  • 胃肠病学 胃肠病学
  • 微生物学 微生物学
  • 临床药房 临床药房

背景情况:

  • 传染性腹仍然是一个重要的健康问题,随着流行病学和病因学的发展.
  • 美国传染病学会2017年指导方针为管理提供了基础.
  • 了解传染性腹对个人和社区的影响至关重要.

研究的目的:

  • 提出一个多学科的方法来管理传染性腹.
  • 突出传染性腹流行病学,病因和表现方面的最新情况.
  • 讨论诊断和新兴治疗策略的进展.

主要方法:

  • 关于传染性腹的当前文献和指导方针的审查.
  • 从传染病,胃肠病学,微生物学和药学角度整合观点.
  • 对诊断方式的分析,包括基于分子和培养的测试.
  • 评估新出现的抗菌素耐药性和生物治疗方案.

主要成果:

  • 传染性腹具有各种急性,慢性和后传染性表现.
  • 分子诊断 (文化独立的诊断测试) 和传统培养方法在诊断和监测中起着至关重要的作用.
  • 抗菌素耐药性是传染性腹管理中的一个越来越大的挑战.
  • 生物疗法提供了一个有希望的策略,以减轻传染性腹的负担.

结论:

  • 合作,多学科的方法对于最佳的传染性腹护理是必不可少的.
  • 对流行病学,诊断和治疗的最新知识对于有效的管理至关重要.
  • 解决抗菌素耐药性和探索生物治疗是未来的关键方向.